<DOC>
	<DOCNO>NCT01606345</DOCNO>
	<brief_summary>The purpose study learn well drug valrubicin ( VALSTAR® ) work help treat patient 's cancer administer nephrostomy tube insert back kidney . The study also do determine safe easy tolerate valrubicin specific dose level , well way drug eliminate human body ( Pharmacokinetics PK ) .</brief_summary>
	<brief_title>Phase I Study Percutaneous Valrubicin Upper Tract Urothelial Carcinoma</brief_title>
	<detailed_description>Eligible patient receive percutaneous valrubicin begin sooner 10 day follow nephrostomy placement within 6 week tumor treatment/resection . Therapy administer one three dose level 3 + 3 design ( 200 mg/75 ml diluent , 400 mg/75 ml diluent 800 mg/75 ml diluent ) . It anticipate least 3 patient accrue 200 400 mg dose level . Assuming acceptable toxicity , accrual target 800 mg dose level 9 patient . If maximum tolerate dose determine 200 mg 400 mg , expansion 9 patient occur maximum tolerate dose ( MTD ) dose level . Drug administer weekly basis 8 total treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Valrubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Zubrod : Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Tissue confirmation UTUC Available tumor grade information Treated UTUC ( complete resection fulguration tumor safely possible , base judgment investigator base visual inspection involve kidney ureter ) least one follow : Low grade urothelial carcinoma Percutaneous upper tract Bacillus CalmetteGuérin ( BCG ) failure : High grade urothelial carcinoma Carcinoma situ ( CIS ) imperative indication nephron preservation ( solitary kidney , renal insufficiency , bilateral upper tract tumor , etc . ) determine study Principal Investigators ( PIs ) Contraindications percutaneous BCG ( e.g . previous adverse systemic local reaction BCG exposure judge PIs , immunosuppression , contraindication BCG therapy ) : High grade urothelial carcinoma CIS imperative indication nephron preservation ( solitary kidney , renal insufficiency , bilateral upper tract tumor , etc . ) determine study PIs Normal prothrombin time ( PT ) , partial thromboplastin time ( PTT ) , international normalize ratio ( INR ) Platelets 100 x 10^9/l great Absolute neutrophil count ( ANC ) 1.5 x 10^9/l great Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 3 x upper limit normal ( ULN ) less Able receive valrubicin within 6 week initial surgery within 6 week second look surgical procedure Radiographic pathologic evidence locally advance ( muscle invasion , lymphovascular invasion , lymphadenopathy , renal parenchymal invasion ) distant metastatic disease Contraindications percutaneous nephrostomy ( i.e . bleed diathesis and/or patient must maintain therapeutic dos warfarin antiplatelet agent valrubicin administer ) . Note : 81 mg aspirin acceptable . Evidence renal/ureteral obstruction determine radiographic study ( antegrade nephrostogram , Intravenous pyelography ( IVP ) , Computed tomography ( CT ) urogram , retrograde pyelogram , lasix renogram , combination thereof ) Contraindication percutaneous administration valrubicin , metabolite valrubicin , know hypersensitivity anthracyclines polyoxyl castor oil . Symptomatic urinary tract infection base combination urinalysis urine culture patient symptom ( i.e . Fever ) . Investigators expect patient abnormal urinalysis base indwell urinary device prior surgical treatment . Urolithiasis involve ipsilateral kidney ( include punctuate calcification suspect renal parenchymal papillary tip calcification see radiographic study visualize endoscopically ) Patient renal replacement therapy ( hemodialysis peritoneal dialysis ) Extravasation contrast visualize antegrade nephrostogram study . ( Note : At initial nephrostogram possibly perform operating room initial percutaneous nephrostomy placement , extravasation visualize . However , procedure prior drug administration confirm extravasation present ) . Concurrent malignancy ( except basal cell carcinoma skin , squamous cell carcinoma skin , concurrent nonmuscle invasive bladder cancer completely resect ) Congenital acquire immunodeficiency Positive pregnancy test plan future pregnancy Expected poor compliance judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Upper Tract Urothelial Carcinoma</keyword>
	<keyword>UTUC</keyword>
	<keyword>Kidney</keyword>
	<keyword>Cancer</keyword>
	<keyword>Renal</keyword>
</DOC>